The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia

Exclusion Criteria

• •Pregnant women or women who could become pregnant during the study.
• •Patients not affiliated with the French universal health care system.
• •Patients who are protected adults according to the terms of the law (French public health laws).
• •Refusal to give consent.
• •Patients whose HHT diagnosis has not be confirmed clinically and/or by molecular biology.
• •Infectious episode.
• •Patients presenting unchecked hypertension at the time of inclusion (systolic BP \> 150 mmHg and/or diastolic BP \> 100 mmHg) with or without treatment. -Patients with hypertension can be included, once blood pressure levels have been controlled by appropriate medical treatment.
• •Participation in another therapeutic trial in the 28 days before inclusion. Patients who have already being treated with bevacizumab by intravenous infusion.
• •A known hypersensitivity to the active substance or one of its excipients.A known hypersensitivity to products containing Chinese hamster ovarian (CHO) cells or to other human or humanized recombinant antibodies.